Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05879432

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Led by Arch Biopartners Inc. · Updated on 2026-05-05

240

Participants Needed

9

Research Sites

142 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.

CONDITIONS

Official Title

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female 18 years of age or older
  • Scheduled for non-emergent coronary and/or valve surgery requiring on-pump cardiopulmonary bypass, including CABG and valve replacements or repairs
  • Have chronic kidney disease stage 3 (eGFR 30 to less than 60 mL/min/1.73 m2) with one or more additional risk factors, or stage 2 (eGFR 60 to less than 90 mL/min/1.73 m2) with one or more additional risk factors such as age 75 or older, combined valve and coronary surgery, low left ventricular ejection fraction (35% or less), elevated urinary biomarkers, diabetes, hypertension, or hyperlipidemia
  • Sexually active women of child-bearing potential must use acceptable birth control throughout the study and have a negative pregnancy test at screening
  • Patient or legally authorized representative available and willing to provide informed consent
Not Eligible

You will not qualify if you...

  • Acute kidney injury present at time of randomization
  • Off-pump cardiac surgery
  • Surgery under circulatory arrest or hypothermia with rectal temperature below 28°C
  • Severe chronic kidney disease with eGFR below 30 mL/min/1.73 m2 or requiring dialysis
  • Imminent or recent aortic dissection surgery
  • Surgery to correct major congenital heart defects (except bicuspid aortic valve)
  • Active cancer that may affect study results
  • Known or suspected sepsis at screening
  • Pregnancy or lactation
  • Known allergy to study drug or its ingredients
  • Participation in another interventional trial or investigational drug treatment within 30 days before study drug and during study
  • Any disease or factors that could confound study outcomes as judged by the investigator
  • Inability to comply with study protocol requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary

Calgary, Alberta, Canada, T2N 4N1

Actively Recruiting

2

Royal Columbian Hospital

New Westminster, British Columbia, Canada, V3L 0A2

Actively Recruiting

3

Unity Health Toronto, St. Michael's Hospital

Toronto, Ontario, Canada, M5B 1W8

Actively Recruiting

4

University Health Network, Toronto General Hospital

Toronto, Ontario, Canada, M5G 1L7

Actively Recruiting

5

Gazi University

Yenimahalle, Ankara, Turkey (Türkiye), 06560

Actively Recruiting

6

Kosuyolu High Specialization Training and Research Hospital

Kartal, Istanbul, Turkey (Türkiye), 34865

Actively Recruiting

7

Erciyes University, Faculty of Medicine - Semiha Kibar Organ Transplant & Dialysis Hospital

Melikgazi, Kayseri, Turkey (Türkiye), 38030

Actively Recruiting

8

Kocaeli University, Faculty of Medicine Practices and Research Hospital

İzmit, Kocaeli, Turkey (Türkiye), 41001

Actively Recruiting

9

Sütçü İmam University, Faculty of Medicine

Kahramanmaraş, Onikişubat, Turkey (Türkiye), 46040

Actively Recruiting

Loading map...

Research Team

R

Richard Muruve

CONTACT

D

David Luke

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here